Loading patent…
AssigneeTokyo Metropolitan Institute of Medical Science
InventorsMakoto HASHIMOTO, Kazunari SEKIYAMA, Yoshiki TAKAMATSU, Masayo FUJITA, Akio SEKIGAWA
Estimating the term…
The present invention was accomplished for the purpose of developing a method for effectively treating and/or preventing synucleinopathies, and is based on a discovery that an adiponectin receptor agonist suppresses α (alpha)-synuclein aggregation, tau phosphorylation and a decrease in proteasomal activity. The method of the present invention for treating and/or preventing neurodegenerative diseases includes a step of administering an effective dose of at least one effective element selected from a group consisting of: adiponectin as an adiponectin receptor agonist; a compound inducing expression of adiponectin; globular adiponectin; and a compound inducing expression of globular adiponectin. The present invention further provides a screening method of the adiponectin receptor agonist for treating and/or preventing neurodegenerative diseases.
A method for treating and/or preventing neurodegenerative diseases, comprising a step of administering an effective dose of an adiponectin receptor agonist and/or a compound inducing said agonist.
A screening method for a compound that inhibits and/or improves neurodegeneration by suppressing α (alpha)-synuclein aggregation, aggregation of phosphorylated tau and/or a decrease in proteasomal activity through adiponectin.
Dependencies are inferred from the claim text.